Bessemer Group
KROS icon

Bessemer Group’s Keros Therapeutics KROS Stock Holding History

Bessemer Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Hold
143,853
– – ﹤0.01% 908
2026
Q1 		$1.59M Hold
143,853
– – ﹤0.01% 857
2025
Q4 		$2.93M Buy
+143,853
New +$2.52M ﹤0.01% 732
2024
Q4 		– Sell
-25
Closed -$1K – 2574
2024
Q3 		$1K Buy
+25
New +$1.24K ﹤0.01% 2454

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bessemer Group's KROS Position: Q2 2026 in Review

Bessemer Group held its Keros Therapeutics (KROS) position steady in Q2 2026 at 143,853 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Bessemer Group first reported a position in KROS in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.93M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Bessemer Group held 143,853 shares of Keros Therapeutics worth $1.54M as of Q2 2026.
  • Bessemer Group left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #908 holding.
  • Bessemer Group first reported a position in Keros Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Bessemer Group's Keros Therapeutics position peaked at $2.93M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.